The increasing prevalence of overactive bladder, faecal incontinence, and chronic pelvic pain is fueling a surge in demand for sacral nerve stimulators in Australia. Against this backdrop, the sacral nerve stimulators market in Australia is set to grow at a compound annual growth rate (CAGR) of 5 per cent between 2023 and 2033, forecasts GlobalData.
GlobalData’s latest report, “Neuromodulation Devices Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033” reveals that the Australian sacral nerve stimulators market accounted for approximately 7 per cent of the Asia-Pacific market in 2023.
Kanchan Chauhan, Medical devices analyst at GlobalData states, “With increasing awareness of pelvic floor disorders and related conditions among both patients and healthcare providers, there is a growing demand for sacral nerve stimulators as a viable treatment option. This surge is further driven by the ageing population, which is more susceptible to these conditions.”
Axonics’ recent regulatory approval from the Therapeutic Goods Administration (TGA) to market its F15 recharge-free sacral neuromodulation (SNM) system in Australia marks a significant advancement in pelvic floor disorder management. The system introduces a recharge-free option, eliminating the hassle of frequent battery replacements while ensuring relief for adults grappling with overactive bladders in the region. The innovative features and patient-centric design of the Axonics F15 system are tailored to enhance patient outcomes and improve quality of life.
Chauhan concludes, “As technological advancements are being made, the focus is on creating solutions that offer advanced features such as compact design, MRI compatibility, and prolonged battery duration, ensuring high efficacy and convenience. The advancements are expected to ensure a promising future for pelvic health innovations.”